Kenya’s Pharmacy and Poisons Board (KPPB) has issued a notice to show its approval for the emergency use of Russia’s Sputnik V Covid-19 vaccine in the Country.
According to the notice, there was successful evaluation process that informed their decision to authorize the emergency use authorization to AstraZeneca vaccine and the Sputnik V vaccine.
The notice on the Boards official twitter handle clarified that this is not a registration but said that the application for Emergency Use Authorization of Russia’s Sputnik V vaccine has been approved after it met all requirements.
“In reviewing the Sputnik V vaccine, the board gave its confirmation after it considered all aspects of quality, safety and efficacy,” read the notice in part, adding that the vaccine is wholesomely safe.
The notice further clarified that the Board continues to review the safety of all authorized products in the market.
Sputnik V is a Covid-19 vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology, and while it has been authorized for emergency use, it is yet to be included in the National Vaccination Program by the Ministry of Health.
Kenya early this month received the first batch of Astra Zeneca Vaccine, a milestone promises for a better tomorrow following an otherwise difficult year in dealing with the ravages of the COVID-19 pandemic.
The 1.02 million doses of the Astra Zeneca-Oxford COVID-19 vaccine, arrived at Jomo Kenyatta International Airport, Nairobi, on March 3, 2021 as part of the COVAX facility.
Kenya’s COVID-19 positivity rate is now at 22.1 percent after 1,127 more people tested positive in the last 24 hours from a sample size of 5,390.
by Alice Gworo
